Pulmonary Vein Isolation (PVI) Combined With Renal Denervation (RDN) in Atrial Fibrillation (AF) and Hypertension (HTN)

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-75
SponsorThe First Affiliated Hospital of Xiamen University

About this trial

The close relationship between the increase of sympathetic tension, AF, and HTN cannot be ignored. In addition, the significant failure rate of PVI (20-50%) in the treatment of AF makes it very necessary to explore the effect of RDN on AF. Therefore, this study aims to compare the effects and safety of PVI alone and PVI combined with RDN with AF combined with HTN, which will open a new chapter for PVI combined with RDN in the treatment of AF.

Eligibility criteria

Qualifiers

18<age<75years

clinic blood pressure≥140/90mmHg or 24-hour ambulatory blood pressure monitoring average blood pressure ≥135/85mmHg

Ecg diagnosis of atrial fibrillation ;

who signed informed consent and were approved by the Ethics Committee of the First Affiliated Hospital of Xiamen University.

Disqualifiers

pregnant women or lactating patients;

Patients who were unsuitable for ablation before surgery (unilateral or bilateral renal artery shape and structure were found: renal artery stenosis exceeding 50%, renal aneurysm, previous renal artery interventional surgery, renal artery malformation, renal artery diameter < 4mm or length of treatable segment < 20mm)

Patients who only have one kidney or have a history of kidney transplantation

Patients with a history of renal arterial intervention or renal denervation

Trial design

Treatments tested in this trial

  • Renal Denervation operation
  • Pulmonary vein isolation

Treatment groups

120 Participants
are divided into 2 treatment groups